Superparamagnetic iron oxide nanoparticles conjugated with folic acid for dual target-specific drug delivery and MRI in cancer theranostics

Huang, Yeu‐Shiang; Mao, Kaili; Zhang, Baolin; Zhao, Ying‐Zheng

doi:10.1016/j.msec.2016.09.052

Cited by 164 publications

(78 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a research by Huang, Mao, Zhang, and Zhao (), MNPs co‐coated with PEG and PEI polymers were synthesized by an improved polyol method in order to target delivery of DOX and imaging (theranostics) with mean hydrodynamic diameters of 67 nm. Excellent FA receptor‐mediated endocytosis was implicated by means of confocal laser scanning microscope.…”

Section: Metal‐ and Nonmetal‐based Nps In Drug Deliverymentioning

confidence: 99%

Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems

Narmani

Rezvani

Farhood

et al. 2019

Drug Development Research

133

View full text Add to dashboard Cite

Conventional chemotherapeutic approaches in cancer therapy such as surgery, chemotherapy, and radiotherapy have several disadvantages due to their nontargeted distributions in the whole body. On the other hand, nanoparticles (NPs) based therapies are remarkably progressing to solve several limitations of conventional drug delivery systems (DDSs) including nonspecific biodistribution and targeting, poor water solubility, weak bioavailability and biodegradability, low pharmacokinetic properties, and so forth. The enhanced permeability and retention effect escape from Pglycoprotein trap in cancer cells as a passive targeting mechanism, and active targeting strategies are also other most important advantages of NPs in cancer diagnosis and therapy. Folic acid (FA) is one of the biologic molecules which has been targeted overexpressed-folic acid receptor (FR) on the surface of cancer cells. Therefore, conjugation of FA to NPs most easily enhances the FR-mediated targeting delivery of therapeutic agents. Here, the recent works in FA which have been decorated NPs-based DDSs are discussed and cancer therapy potency of these NPs in clinical trials are presented. K E Y W O R D Scancer diagnosis and therapy, folic acid, nanoparticles, nanotechnology, targeted drug delivery

show abstract

Section: Metal‐ and Nonmetal‐based Nps In Drug Deliverymentioning

confidence: 99%

Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems

Narmani

Rezvani

Farhood

et al. 2019

Drug Development Research

133

View full text Add to dashboard Cite

show abstract

“…This makes magnetic nanoparticles (MNPs) excellent contrast agents (CAs) in MRI [3][4][5]. Their strong magnetization also allows them to be fixed, moved, tagged or detected magnetically thus making them useful in bioseparation, diagnosis or in targeted drug delivery [6,7]. Moreover, they can also respond resonantly to an alternating magnetic field and induce heating, therefore being of interest for magnetic-induced hyperthermia [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Polymer-coated superparamagnetic iron oxide nanoparticles as T₂ contrast agent for MRI and their uptake in liver

et al. 2019

View full text Add to dashboard Cite

Aim:To study the efficiency of multifunctional polymer-based superparamagnetic iron oxide nanoparticles (bioferrofluids) as a T 2 magnetic resonance contrast agent and their uptake and toxicity in liver. Materials & methods: Mice were intravenously injected with bioferrofluids and Endorem R . The magnetic resonance efficiency, uptake and in vivo toxicity were investigated by means of magnetic resonance imaging (MRI) and histological techniques. Results: Bioferrofluids are a good T 2 contrast agent with a higher r 2 /r 1 ratio than Endorem. Bioferrofluids have a shorter blood circulation time and persist in liver for longer time period compared with Endorem. Both bioferrofluids and Endorem do not generate any noticeable histological lesions in liver over a period of 60 days post-injection. Conclusion: Our bioferrofluids are powerful diagnostic tool without any observed toxicity over a period of 60 days post-injection.Lay abstract: Several superparamagnetic iron oxide nanoparticles (SPIONs) preparations have been approved by US FDA for clinical use as MRI contrast agents. In recent years, we have been developing a synthetic multifunctional platform for SPIONs based on the use of polymers. In this report, we explored the diagnostic potential of these nanoparticles (herein called bioferrofluids) as an MRI contrast agent and their uptake in liver, without neglecting their toxicological effects. Results show that our bioferrofluids are a good T 2 contrast agent without any observed toxicity in liver.

show abstract

“…Due to their magnetic properties, with a diameter ranging from a few nanometers up to approximately 100 nm, iron oxide particles have been evaluated and used in several magnetic resonance technology-based biomedical applications such as multifunctional theranostic complexes combining tumor targeting, imaging as well as cancer nanotherapy in personalized cancer treatment [91,92,93,94,95,96,97,98,99,100]. The superparamagnetic iron oxide NPs (SPIONs) are most often used, and the subpopulation of ultrasmall SPIONs denoted as USPIOs defined as having a diameter of less than ~20 nm.…”

Section: Nanoparticles For Prostate and Breast Cancermentioning

confidence: 99%

Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications—Focus on Prostate and Breast Cancer

Elgqvist

2017

IJMS

View full text Add to dashboard Cite

Prostate and breast cancer are the second most and most commonly diagnosed cancer in men and women worldwide, respectively. The American Cancer Society estimates that during 2016 in the USA around 430,000 individuals were diagnosed with one of these two types of cancers, and approximately 15% of them will die from the disease. In Europe, the rate of incidences and deaths are similar to those in the USA. Several different more or less successful diagnostic and therapeutic approaches have been developed and evaluated in order to tackle this issue and thereby decrease the death rates. By using nanoparticles as vehicles carrying both diagnostic and therapeutic molecular entities, individualized targeted theranostic nanomedicine has emerged as a promising option to increase the sensitivity and the specificity during diagnosis, as well as the likelihood of survival or prolonged survival after therapy. This article presents and discusses important and promising different kinds of nanoparticles, as well as imaging and therapy options, suitable for theranostic applications. The presentation of different nanoparticles and theranostic applications is quite general, but there is a special focus on prostate cancer. Some references and aspects regarding breast cancer are however also presented and discussed. Finally, the prostate cancer case is presented in more detail regarding diagnosis, staging, recurrence, metastases, and treatment options available today, followed by possible ways to move forward applying theranostics for both prostate and breast cancer based on promising experiments performed until today.

show abstract

Superparamagnetic iron oxide nanoparticles conjugated with folic acid for dual target-specific drug delivery and MRI in cancer theranostics

Cited by 164 publications

References 49 publications

Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems

Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems

Polymer-coated superparamagnetic iron oxide nanoparticles as T₂ contrast agent for MRI and their uptake in liver

Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications—Focus on Prostate and Breast Cancer

Contact Info

Product

Resources

About

Superparamagnetic iron oxide nanoparticles conjugated with folic acid for dual target-specific drug delivery and MRI in cancer theranostics

Cited by 164 publications

References 49 publications

Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems

Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems

Polymer-coated superparamagnetic iron oxide nanoparticles as T2 contrast agent for MRI and their uptake in liver

Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications—Focus on Prostate and Breast Cancer

Contact Info

Product

Resources

About

Polymer-coated superparamagnetic iron oxide nanoparticles as T₂ contrast agent for MRI and their uptake in liver